(Q22251018)

Dimensions Publication ID

Dimensions

1025657218

7 February 2023

Michael Kometer

series ordinal

2

author given names

Michael

author last names

Kometer

1 reference

Dimensions Publication ID

Dimensions

1025657218

Nature Reviews Neuroscience

7 February 2023

language of work or name

English

0 references

publication date

18 August 2010

0 references

published in

0 references

volume

11

0 references

issue

9

0 references

page(s)

642-651

0 references

cites work

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study

1 reference

Personality structure as the main determinant of drug induced (model) psychoses.

31 March 2020

1 reference

Effects of mescaline and lysergic acid (d-LSD-25)

31 March 2020

1 reference

The Early Symptoms of Schizophrenia

31 March 2020

1 reference

Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study

31 March 2020

1 reference

Serotonin research: contributions to understanding psychoses

31 March 2020

1 reference

31 March 2020

1 reference

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

31 March 2020

1 reference

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

31 March 2020

1 reference

Psychological aspects of the LSD treatment of the neuroses

31 March 2020

1 reference

Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom

31 March 2020

1 reference

Psychedelic Therapy Utilizing LSD in the Treatment of the Alcoholic Patient: A Preliminary Report

31 March 2020

1 reference

Glutamate-based antidepressants: 20 years on.

31 March 2020

1 reference

Antidepressant effects of ketamine in depressed patients

31 March 2020

1 reference

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

31 March 2020

1 reference

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist

31 March 2020

1 reference

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

31 March 2020

1 reference

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

31 March 2020

1 reference

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

31 March 2020

1 reference

How can we realize the promise of personalized antidepressant medicines?

31 March 2020

1 reference

Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.

31 March 2020

1 reference

Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.

31 March 2020

1 reference

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

31 March 2020

1 reference

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up

31 March 2020

1 reference

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

31 March 2020

1 reference

LSD treatment in a severe case of compulsive neurosis

31 March 2020

1 reference

Response of cluster headache to psilocybin and LSD.

31 March 2020

1 reference

Agonist-trafficking and hallucinogens.

31 March 2020

1 reference

Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines

31 March 2020

1 reference

Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?

31 March 2020

1 reference

A defined network of fast-spiking interneurons in orbitofrontal cortex: responses to behavioral contingencies and ketamine administration

31 March 2020

1 reference

Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms

31 March 2020

1 reference

Neurocognitive mechanisms in depression: implications for treatment

31 March 2020

1 reference

Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis

31 March 2020

1 reference

Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents

31 March 2020

1 reference

Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release

31 March 2020

1 reference

5HT-2 mediation of acute behavioral effects of hallucinogens in rats

31 March 2020

1 reference

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

31 March 2020

1 reference

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

31 March 2020

1 reference

Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo

31 March 2020

1 reference

In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents

31 March 2020

1 reference

Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex

31 March 2020

1 reference

Serotonin and Hallucinogens

31 March 2020

1 reference

A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex

31 March 2020

1 reference

Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices

31 March 2020

1 reference

AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes

31 March 2020

1 reference

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis

31 March 2020

1 reference

Hallucinogen-induced UP states in the brain slice of rat prefrontal cortex: role of glutamate spillover and NR2B-NMDA receptors

31 March 2020

1 reference

Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors.

31 March 2020

1 reference

Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors

31 March 2020

1 reference

5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

31 March 2020

1 reference

Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling

31 March 2020

1 reference

Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex

31 March 2020

1 reference

Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A.

31 March 2020

1 reference

Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907.

31 March 2020

1 reference

Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm.

31 March 2020

1 reference

Antisense inhibition of 5-hydroxytryptamine2a receptor induces an antidepressant-like effect in mice.

31 March 2020

1 reference

Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors

31 March 2020

1 reference

Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression.

31 March 2020

1 reference

Anxiolytic effect and memory improvement in rats by antisense oligodeoxynucleotide to 5-hydroxytryptamine-2A precursor protein

31 March 2020

1 reference

Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice.

31 March 2020

1 reference

Experiential and genetic contributions to depressive- and anxiety-like disorders: clinical and experimental studies

31 March 2020

1 reference

Corticotropin-releasing factor receptor antagonism within the dorsal raphe nucleus reduces social anxiety-like behavior after early-life social isolation

31 March 2020

1 reference

Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression

31 March 2020

1 reference

CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling

31 March 2020

1 reference

Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder

31 March 2020

1 reference

Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus

31 March 2020

1 reference

A PET [18F]altanserin study of 5-HT2A receptor binding in the human brain and responses to painful heat stimulation

31 March 2020

1 reference

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

31 March 2020

1 reference

Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.

31 March 2020

1 reference

NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex

31 March 2020

1 reference

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

31 March 2020

1 reference

Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway

31 March 2020

1 reference

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

31 March 2020

1 reference

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

31 March 2020

1 reference

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

31 March 2020

1 reference

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

31 March 2020

1 reference

Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence.

31 March 2020

1 reference

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

31 March 2020

1 reference

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

31 March 2020

1 reference

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.

31 March 2020

1 reference

M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats

31 March 2020

1 reference

Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.

31 March 2020

1 reference

The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats

31 March 2020

1 reference

Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex

31 March 2020

1 reference

Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.

31 March 2020

1 reference

Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine

31 March 2020

1 reference

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

31 March 2020

1 reference

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.

31 March 2020

1 reference

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

31 March 2020

1 reference

Cerebral interregional correlations of associative language processing: a positron emission tomography activation study using fluorine-18 fluorodeoxyglucose

31 March 2020

1 reference

Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.

31 March 2020

1 reference

The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression.

31 March 2020

1 reference

Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy.

31 March 2020

1 reference

Trait anxiety and impoverished prefrontal control of attention

31 March 2020

1 reference

Neural mechanisms underlying selective attention to threat

31 March 2020

1 reference

Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression.

31 March 2020

1 reference

Functional coupling of the amygdala in depressed patients treated with antidepressant medication

31 March 2020

1 reference

Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study

31 March 2020

1 reference

Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study

31 March 2020

1 reference

New insights into BDNF function in depression and anxiety

31 March 2020

1 reference

Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia

31 March 2020

1 reference

Ketamine and the next generation of antidepressants with a rapid onset of action

31 March 2020

1 reference

5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex.

31 March 2020

1 reference

Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats

31 March 2020

1 reference

Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats.

31 March 2020

1 reference

Psychiatric safety of ketamine in psychopharmacology research

31 March 2020

1 reference

LSD in the Treatment of Alcoholics*

31 March 2020

1 reference

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

31 March 2020

1 reference

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

31 March 2020

1 reference

The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.

31 March 2020

1 reference

Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.

31 March 2020

1 reference

A Cartography of the Ecstatic and Meditative States

31 March 2020

1 reference

A review of the clinical effects of psychotomimetic agents

31 March 2020

1 reference

LSD in the supportive care of the terminally ill cancer patient

31 March 2020

1 reference

A Controlled Comparison of Lysergic Acid Diethylamide (LSD) and Dextroamphetamine in Alcoholics

31 March 2020

1 reference

Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study

31 March 2020

1 reference

The Use of Ketamine in Psychiatry

31 March 2020

1 reference

Further observations regarding hallucinogenic treatment

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRN2884

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

812283

1025657218

0 references

812283

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference